According to pharmaceutical market research giant IMS Health, global pharma sales grew 5.1% to $956 billion between 2010 and 2011. This represented an all-time high and was nearly double the level of $503 billion back in 2003. Growth has slowed from closer to 9% annually roughly a decade ago, but continues to advance at a very healthy clip. Below is an overview of five of the best-selling individual drugs of all time.

By a wide margin, Pfizer's Lipitor qualifies as the best-selling drug of all time. The blockbuster drug, which is used to lower cholesterol levels, was first introduced to the market in 1997 and had a strong run of exclusivity until its patent expired in late 2011. Its rise in popularity was attributed to the fact it lowered cholesterol faster than competing statin drugs, according to certain studies. One source put the drug's total sales up through 2011 at around $125 billion cumulatively. This included peak revenue years above $10 billion annually during 2009 and 2010. Sales have fallen dramatically now that the drug faces generic competition.

Plavix is offered by the pharma giants Sanofi and Bristol-Myers Squibb and is used to help lower the risk of heart attack or stroke. Like Lipitor, Plavix now faces generic competition and saw the approval of seven companies to sell the identical generic version in pharmacies back in May. However, it had a long run of annual sales levels in the multi-billion-dollar range. Its 2011 rank was number two at $9.3 billion in sales, which put it just behind Lipitor. For the five-year period between 2007 and 2011, Plavix logged total sales of $43.2 billion to place it firmly among the top-selling drugs of all time.

Seretide logged 2011 sales of $8.7 billion, which was its best year ever. The drug is sold by GlaxoSmithKline and is used to treat asthma. Seretide saw generic competition a couple of years ago in many of its global markets, but still holds protection in others, which is helping it hold onto many billions in annual sales. The compound is also said to be difficult to copy, which helps keep Glaxo's original version selling well.

Crestor is another cholesterol-lowering drug that competes with Lipitor and the wide range of current generic alternatives. The drug's owner is pharma giant AstraZeneca, and it appears the drug maintains patent protection in most of its large markets. In 2011, it was the fourth best-selling drug at $8 billion. This qualified as its best year ever, and the expiration of a couple of larger drugs above should allow Crestor to continue to build on its ranking as one of the best-selling drugs.

Humira is Abbott Laboratories' popular anti-arthritis drug. With Lipitor falling by the wayside, Humira is set to become the world's best-selling drug in 2012. Its 2011 sales came in at $7.3 billion, but sales are constantly on the rise. The drug is growing briskly and is the envy of rivals who have seen drugs fall by the wayside due to generic competition.

The Bottom Line
The patent expiration cliff of many blockbuster drugs makes it unlikely that many druge in the future will log sales above $10 billion annually. However, $1 billion in annual sales is all that is needed to technically qualify a drug as a blockbuster drug. Many of the above prescription medications should continue to achieve these sales levels in the near future despite the fact that many are already seeing generic competition.

Related Articles
  1. Mutual Funds & ETFs

    ETF Analysis: Direxion Daily Healthcare Bull 3X

    Learn about the Direxion Daily Healthcare Bull. This is a leveraged ETF that tracks the health care sector, which is a leader in this bull market.
  2. Stock Analysis

    2 Catalysts Driving Intrexon to All-Time Highs

    Examine some of the main reasons for Intrexon stock tripling in price between 2014 and 2015, and consider the company's future prospects.
  3. Economics

    Understanding Switching Costs

    Consumers incur switching costs when they receive a monetary or other type of penalty for changing a supplier, brand or product.
  4. Investing

    What’s Holding Back the U.S. Consumer

    Even as job growth has surged and gasoline prices have plunged, U.S. consumers are proving slow to respond and repair their overextended balance sheets.
  5. Economics

    Explaining Market Penetration

    Market penetration is the measure of how much a good or service is being used within a total potential market.
  6. Economics

    Calculating the Marginal Rate of Substitution

    The marginal rate of substitution determines how much of one good a consumer will give up to obtain extra units of another good.
  7. Mutual Funds & ETFs

    ETF Analysis: ProShares UltraPro Nasdaq Biotech

    Obtain information about an ETF offerings that provides leveraged exposure to the biotechnology industry, the ProShares UltraPro Nasdaq Biotech Fund.
  8. Stock Analysis

    5 Reasons Thoratec Corp. Keeps Impressing Investors

    Learn about Thoratec Corporation and its position in its industry. Understand five key factors why the company has impressed investors.
  9. Stock Analysis

    The 2 Healthcare Stocks You'll Wish You Bought in 2015

    Learn about the health care industry and the companies involved. Understand why the two best performing health care stocks in 2015 did so well.
  10. Stock Analysis

    The 5 Worst Health Care Stocks of 2015

    Learn about the health care industry and how it has performed in 2015. Understand why the worst-performing health care stocks of 2015 have underperformed.
  1. Duty Free

    Goods that international travelers can purchase without paying ...
  2. Mobile Health

    Mobile health is the practice of medicine using new mobile technologies.
  3. Medical Identity Theft

    Stealing another person’s health insurance information so that ...
  4. Case Management

    Planning, processing and monitoring the healthcare services given ...
  5. Medical Patent

    A legal protection against market competition that a government ...
  6. Fast-Moving Consumer Goods (FMCG)

    These are consumer goods products that sell quickly at relatively ...
  1. What role does the agency problem play in the modern Health Care industry?

    Agency problems vary from health care system to health care system, and not all economists agree on the degree and desirability ... Read Full Answer >>
  2. What does marginal utility tell us about consumer choice?

    In microeconomics, utility represents a way to relate the amount of goods consumed to the amount of happiness or satisfaction ... Read Full Answer >>
  3. What are some common ways product differentiation is achieved?

    There are many ways to achieve product differentiation, some more common than others. Horizontal Differentiation Horizontal ... Read Full Answer >>
  4. What is the difference between an OEM (original equipment manufacturer) and a VAR ...

    An original equipment manufacturer (OEM) is a company that manufactures a basic product or a component product, such as a ... Read Full Answer >>
  5. Is the retail sector also affected by seasonal factors?

    Generally speaking, the retail sector is highly seasonal. Almost invariably, sales in the retail sector are highest in the ... Read Full Answer >>
  6. What has the retail sector evolved to its current structure?

    Retail is the catch-all phrase for the sale of final goods to consumers; a retail transaction is considered an "end" and ... Read Full Answer >>

You May Also Like

Trading Center

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!